APA

Griswold D. E., Webb E. F., Badger A. M., Gorycki P. D., Levandoski P. A., Barnette M. A., Grous M., Christensen S. & Torphy T. J. (19981207). SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. : The Journal of pharmacology and experimental therapeutics.

Chicago

Griswold D E, Webb E F, Badger A M, Gorycki P D, Levandoski P A, Barnette M A, Grous M, Christensen S and Torphy T J. 19981207. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. : The Journal of pharmacology and experimental therapeutics.

Harvard

Griswold D. E., Webb E. F., Badger A. M., Gorycki P. D., Levandoski P. A., Barnette M. A., Grous M., Christensen S. and Torphy T. J. (19981207). SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. : The Journal of pharmacology and experimental therapeutics.

MLA

Griswold D E, Webb E F, Badger A M, Gorycki P D, Levandoski P A, Barnette M A, Grous M, Christensen S and Torphy T J. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. : The Journal of pharmacology and experimental therapeutics. 19981207.